Stocks / NASDAQ / DBV Technologies S.A.

DBV Technologies S.A.

Our Opinion

DBV Technologies S.A. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.

Supporting Evidence:

DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis

In the following press release, the company announced the publication of preclinical data in the Journal of Allergy and Clinical Immunology (JACI) suggesting, “Independent of the route of sensitization, treatment with Epicutaneous Immunotherapy (EPIT) provides protection against food induced anaphylaxis during therapy and after treatment discontinuation in animal models.”

Company Description

DBV Technologies SA operates as a biopharmaceutical firm. The Company develops products and immunotherapies for the diagnosis and treatment of various food allergies. DBV Technologies delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin.  [Source: Bloomberg]

Company Website: